StockSelector.com
  Research, Select, & Monitor Thursday, November 21, 2019 9:20:43 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Catalyst Pharmaceuticals, Inc.$4.61$.102.22%

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Catalyst Pharmaceuticals, Inc. has an overall rank of 1464 out of 7176 stocks based on 11 positive rankings and 8 negative rankings.

Positive Rankings
Top Intrinsic Values
Catalyst Pharmaceuticals rank is 23
PEGValue
Catalyst Pharmaceuticals has a PEG Value of $60.92. A stock is commonly considered to be fairly valued when its PE ratio equals its earnings growth rate. The PEG Value is the price where the PE Ratio, based on next year's earnings estimate, divided by the estimated growth rate over the next couple of years equals 1. This implies that if the company maintains its estimated growth rate, that the stock should gain 1,221.54% in the next year. Among companies with a PEG Value above the current stock price, Catalyst Pharmaceuticals is ranked 49.
Low vPut/Call
Catalyst Pharmaceuticals has a low Put/Call ratio of 0.12 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Catalyst Pharmaceuticals is ranked 209.
Highest Cash Growth
Catalyst Pharmaceuticals rank is 257
SSValue
The StockSelector Value for Catalyst Pharmaceuticals is $10.20. The StockSelector Value assumes the market consistently prices a stock around a given PE ratio and, therefore, multiplies the average PE (using forward earnings estimates) over the past three years by future earnings estimates. Among companies with a StockSelector Value above the current stock price, Catalyst Pharmaceuticals is ranked 377.
Low/Rising MACD
The MACD remains negative, but is rising... suggesting a possible near-term correction. Of companies with a negative, but rising MACD, Catalyst Pharmaceuticals is ranked 435.
Debt-to-Equity
Catalyst Pharmaceuticals rank is 439
Low Put/Call
Catalyst Pharmaceuticals has a low Put/Call ratio of 0.22 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Catalyst Pharmaceuticals is ranked 597.
90 Day Gain
Catalyst Pharmaceuticals rank is 859
Up EPS Surprise
Catalyst Pharmaceuticals beat the consensus earnings estimate when it last reported quarterly earnings.
Highest Net Margin
Catalyst Pharmaceuticals rank is 1472
Negative Rankings
Negative Guidance
Within the past 90 days Catalyst Pharmaceuticals has provided guidance belwo the consensus estimates. Statistics show companies that provide negative guidance underperform the market in the short-term.
Missed Whisper
According to EarningsWhispers.com, Catalyst Pharmaceuticals missed the Earnings Whisper number when it last reported earnings. Statistics show that companies that have missed the Earnings Whisper number underperform the market in the short-term.
Down Estimate Revision
During the past month, the consensus earnings estimate for the current year and next year have decreased by a combined (5.32%). Among companies that have had their estimates lowerec within the past month, Catalyst Pharmaceuticals is ranked 436.
Price-to-Book
Catalyst Pharmaceuticals rank is 449
Negative ROA
Catalyst Pharmaceuticals rank is 503
Negative ROE
Catalyst Pharmaceuticals rank is 538
Price-to-Sales
Catalyst Pharmaceuticals rank is 757
10 Day Loss
Catalyst Pharmaceuticals rank is 1891







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.